Citation Impact
Citing Papers
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
An Electrostatic Engine Model for Autoinhibition and Activation of the Epidermal Growth Factor Receptor (EGFR/ErbB) Family
2005
Affinity and Avidity in Antibody-Based Tumor Targeting
2009
Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis
2023 StandoutNobel
Progress and challenges towards targeted delivery of cancer therapeutics
2018 Standout
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
2016
Hallmarks of Cancer: The Next Generation
2011 Standout
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Engineering precision nanoparticles for drug delivery
2020 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Hydrophobic mismatch drives self-organization of designer proteins into synthetic membranes
2024 StandoutNobel
Not just a sink: endosomes in control of signal transduction
2004
Hydroxycholesterol substitution in ionizable lipid nanoparticles for mRNA delivery to T cells
2022 StandoutNobel
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Adjuvant lipidoid-substituted lipid nanoparticles augment the immunogenicity of SARS-CoV-2 mRNA vaccines
2023 StandoutNobel
Purpose-driven biomaterials research in liver-tissue engineering
2010
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Metabolic Regulation of Hematopoietic Stem Cells in the Hypoxic Niche
2011 StandoutNobel
PI3K pathway alterations in cancer: variations on a theme
2008
Evolution and clinical translation of drug delivery nanomaterials
2017
Omics-based nanomedicine: The future of personalized oncology
2013
Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosesitizer conjugates suitable for photodynamic therapy
2007
The Structure of a Receptor with Two Associating Transmembrane Domains on the Cell Surface: Integrin αIIbβ3
2009 StandoutNobel
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
2020
EGF–ERBB signalling: towards the systems level
2006 Standout
Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery
2021 StandoutNobel
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis
2004
Delivery technologies for cancer immunotherapy
2019 Standout
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Mammalian Rho GTPases: new insights into their functions from in vivo studies
2008 Standout
3D bioprinting of tissues and organs
2014 Standout
mTOR: from growth signal integration to cancer, diabetes and ageing
2010 Standout
Microfluidic organs-on-chips
2014 Standout
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
2013
Quantitative modeling perspectives on the ErbB system of cell regulatory processes
2008
A quantitative protein interaction network for the ErbB receptors using protein microarrays
2005 Nature
Endocytosis and intracellular trafficking of ErbBs
2008
Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab
2004
β2-Adrenergic Receptor Signaling and Desensitization Elucidated by Quantitative Modeling of Real Time cAMP Dynamics
2007 StandoutNobel
Large-scale prediction and testing of drug activity on side-effect targets
2012 Nature
Microenvironmental regulation of metastasis
2008 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Endosome maturation
2011 Standout
Trafficking of the ErbB receptors and its influence on signaling
2003
Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks
2006 Standout
Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens
2015 StandoutNobel
Calcium Signaling
2007 Standout
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Cell-signalling dynamics in time and space
2006
Microengineered Liver Tissues for Drug Testing
2015
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Molecular mechanisms of mTOR-mediated translational control
2009 Standout
Quantitative analysis of the activation mechanism of the multicomponent growth-factor receptor Ret
2006
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Time-resolved Mass Spectrometry of Tyrosine Phosphorylation Sites in the Epidermal Growth Factor Receptor Signaling Network Reveals Dynamic Modules
2005
Use of Micropatterned Cocultures to Detect Compounds That Cause Drug-Induced Liver Injury in Humans
2012
Redox Potential and ROS-Mediated Nanomedicines for Improving Cancer Therapy
2017
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
I787 provides signals for c-Kit receptor internalization and functionality that control mast cell survival and development
2010 StandoutNobel
Nanomaterials for In Vivo Imaging
2017
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Surface Biomodification of Liposomes and Polymersomes for Efficient Targeted Drug Delivery
2021
Nanoparticles in the clinic: An update
2019
Wnt/β-Catenin Pathway
2005
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Imaging Tumors with an Albumin-Binding Fab, a Novel Tumor-Targeting Agent
2007
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
ProTox-II: a webserver for the prediction of toxicity of chemicals
2018 Standout
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
2019
Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care
2017
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway
2005
Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines
2017
Cellular uptake of nanoparticles: journey inside the cell
2017 Standout
Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
2023 StandoutNobel
Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
2014
Signalling to eIF4E in cancer
2015
Works of Bart S. Hendriks being referenced
Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study
2017
Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects.
2003
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity
2012
Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer
2016
HER2-Mediated Effects on EGFR Endosomal Sorting: Analysis of Biophysical Mechanisms
2003
Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
2015
64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer
2017
Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients
2013
Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment
2019
A gradient-loadable 64Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography
2014
Wnt signaling: A complex issue
2002
Decreased internalisation of ErbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib
2006
Parsing ERK Activation Reveals Quantitatively Equivalent Contributions from Epidermal Growth Factor Receptor and HER2 in Human Mammary Epithelial Cells
2004
Quantitative Analysis of HER2-mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis
2003
Synergistic drug–cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity
2009
Multiscale Kinetic Modeling of Liposomal Doxorubicin Delivery Quantifies the Role of Tumor and Drug‐Specific Parameters in Local Delivery to Tumors
2012
Abstract C90: HER2-targeted liposomal doxorubicin MM-302 has a favorable cardiosafety profile in preclinical models.
2011
A phase I study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced, HER2-positive (HER2+) breast cancer.
2012
Cytokine-associated drug toxicity in human hepatocytes is associated signaling network dysregulation
2011
Abstract 3637: MM-302, a HER2-targeted liposomal doxorubicin, shows binding/uptake and efficacy in HER2 2+ cells and xenograft models
2011
Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect
2013
Abstract P3-14-09: Preclinical Safety and Activity of MM-302, a HER2-Targeted Liposomal Doxorubicin Designed To Have an Improved Safety and Efficacy Profile over Approved Anthracyclines
2010